Leptin tA Ovine is produced via recombinant expression in E. coli, followed by proprietary chromatographic purification. Its high purity is validated by:
The protein is supplied as a lyophilized powder, requiring reconstitution in sterile water or 0.4% NaHCO₃ (pH 8) to concentrations ≥100 µg/ml .
Leptin tA Ovine inhibits leptin-induced proliferation of BAF/3 cells expressing human ObR (long isoform). Its activity is 6–8× lower than non-PEGylated antagonists due to steric hindrance from PEGylation .
Despite reduced in vitro potency, PEGylation confers prolonged systemic exposure, leading to significant weight gain in rodent models via increased food intake. This contrasts with non-PEGylated antagonists, which show transient effects .
Leptin tA Ovine is utilized to:
Study Leptin Receptor Signaling: Dissect ObR activation mechanisms using competitive antagonists .
Model Obesity and Metabolic Disorders: Induce hyperphagia and weight gain in rodent models to investigate leptin resistance .
Evaluate PEGylation Effects: Compare pharmacokinetics of PEGylated vs. non-PEGylated antagonists in vivo .
Parameter | Leptin tA Ovine | Native Ovine Leptin |
---|---|---|
Receptor Binding | Competes for ObR binding (antagonist) | Activates ObR (agonist) |
Biological Role | Inhibits leptin signaling | Regulates energy balance, growth, and metabolism |
PEGylation | 20 kDa PEG enhances half-life | Non-PEGylated |
Therapeutic Potential | Obesity, leptin-sensitive disorders | Metabolic disorders (e.g., leptin deficiency) |
Leptin is an adipokine secreted by adipose tissue that conveys information on energy stores and regulates both neuroendocrine function and energy homeostasis . Ovine models are particularly valuable in leptin research because sheep exhibit physiological leptin resistance as a seasonal adaptation, unlike the pathological state observed in humans . This natural phenomenon allows researchers to study leptin sensitivity and resistance mechanisms under controlled conditions. Additionally, sheep have metabolic characteristics that make certain findings more translatable to human physiology than rodent studies, particularly regarding seasonal adaptations and energy regulation.
Leptin concentrations in sheep demonstrate significant seasonal variations correlated with photoperiod. During long-day (LD) seasons (summer months), leptin plasma concentrations increase by approximately 180% compared to short-day (SD) seasons (winter months) . This seasonal variation represents a physiological adaptation that allows sheep to increase food intake and store energy during periods of food abundance, despite high leptin levels which would normally suppress appetite. During autumn and winter, sheep exhibit physiological sensitivity to leptin, with appetite adjusting proportionally to nutritional status .
Leptin affects multiple hypothalamic-pituitary axes in sheep, with significant impacts on both the hypothalamic-pituitary-gonadal axis and the hypothalamic-pituitary-somatotropic (HPS) axis . In the gonadal axis, leptin administration stimulates GnRH release, which subsequently affects luteinizing hormone and follicle-stimulating hormone levels, influencing reproductive function . For the somatotropic axis, leptin influences growth hormone (GH) secretion in a season-dependent manner, with greater effects during short-day photoperiods . Unlike in rodents, leptin's effects on the hypothalamic-pituitary-thyroid and hypothalamic-pituitary-adrenal axes appear more limited in sheep, similar to findings in humans .
Research demonstrates a complex, photoperiod-dependent relationship between leptin and growth hormone secretion:
During Short-Day (SD) Photoperiod:
Leptin administration significantly increases GH secretion
Sheep exhibit physiological sensitivity to leptin
LEPR expression in the arcuate nucleus (ARC) is higher
During Long-Day (LD) Photoperiod:
The same dose of leptin fails to influence GH secretion
Sheep exhibit leptin resistance despite higher baseline leptin levels
LEPR expression in the ARC is lower
This differential response suggests a seasonal leptin resistance mechanism affecting the pituitary during LD periods, which appears to be targeted at post-transcriptional stages of GH secretion rather than transcriptional control . This represents an evolutionary adaptation allowing sheep to increase food intake despite elevated leptin levels when food is abundant.
Several molecular mechanisms appear to contribute to seasonal leptin resistance in sheep:
Receptor expression: Lower leptin receptor (LEPR) mRNA expression in the arcuate nucleus during LD periods correlates with decreased leptin sensitivity
Hypothalamic regulation: Different patterns of LEPR expression in the paraventricular nucleus (PVN) in response to leptin treatment between seasons
Differential gene expression: Higher GHRH mRNA expression in the ARC and higher SST mRNA expression in the PVN during LD photoperiod
Regulatory effects: During SD photoperiod, leptin treatment increases LEPR expression in the PVN, while during LD photoperiod, leptin treatment decreases LEPR expression
This complex interplay creates a physiological adaptation allowing sheep to become resistant to leptin's anorectic action during periods of food abundance, representing a fundamentally different process than pathological leptin resistance in human obesity.
The relationship between hypothalamic gene expression and leptin's effects on GH secretion reveals region-specific patterns:
Hypothalamic Structure | Gene | Control SD | Leptin SD | Control LD | Leptin LD |
---|---|---|---|---|---|
Arcuate nucleus (ARC) | GHRH | 1 ± 0.08 A | 1.2 ± 0.04 A | 1.54 ± 0.11 B | 1.72 ± 0.14 B |
LEPR | 1 ± 0.24 B | 0.95 ± 0.17 B | 0.58 ± 0.03 A | 0.66 ± 0.09 A | |
Paraventricular nucleus (PVN) | SST | 1 ± 0.09 A | 1.17 ± 0.15 AB | 1.81 ± 0.4 B | 1.3 ± 0.19 AB |
LEPR | 1 ± 0.13 B | 1.31 ± 0.11 C | 0.91 ± 0.03 B | 0.6 ± 0.08 A |
GHRH mRNA expression in the ARC is significantly higher during LD photoperiod, while leptin administration does not significantly influence its expression in either photoperiod . SST mRNA expression in the PVN is also higher during long days. These patterns suggest that leptin's photoperiod-dependent effects on GH secretion likely involve post-transcriptional mechanisms rather than direct transcriptional regulation of GHRH or SST genes .
Based on established protocols, leptin administration studies in sheep should follow these methodological guidelines:
Animal selection:
Experimental setup:
Leptin administration:
This design allows for rigorous assessment of leptin's effects while accounting for the critical photoperiod variable that significantly impacts results.
The molecular analysis of leptin effects in sheep studies should employ these techniques:
Tissue processing:
RNA analysis workflow:
Gene expression analysis:
The comprehensive primer set provided in the research (including sequences for all key target genes) provides a valuable resource for researchers pursuing these analyses.
When designing leptin studies in sheep, researchers must carefully consider these photoperiod-related factors:
Timing considerations:
Physiological status:
Experimental design:
Failure to account for these photoperiodic effects can lead to contradictory or uninterpretable results, as leptin's actions are fundamentally different between seasons.
Important differences exist in leptin effects between sheep and humans:
These differences highlight why ovine models provide complementary insights to human studies, especially regarding seasonal adaptations in energy regulation and leptin sensitivity mechanisms .
Several notable contradictions exist in research findings regarding leptin's effects on GH secretion:
Species differences:
Seasonal variations:
Central vs. peripheral effects:
These contradictions highlight the complexity of leptin's regulatory roles and the importance of carefully controlled experimental protocols that account for species differences and seasonal variables.
Effective analysis of gene expression data across multiple hypothalamic regions requires:
Reference gene optimization:
Region-specific analysis:
Data representation:
This approach recognizes the functional specialization of hypothalamic nuclei while allowing for meaningful comparisons of leptin's effects across brain regions.
Several promising research directions emerge from current knowledge:
Molecular signaling pathways:
Comparative physiology:
Neural circuit mapping:
These approaches may yield insights applicable to understanding human leptin resistance while leveraging the unique seasonal adaptation of sheep as a natural experimental model.
Translating findings from ovine leptin studies to human research requires:
Mechanistic focus:
Comparative approaches:
Therapeutic implications:
The physiological, reversible nature of ovine leptin resistance offers unique insights that complement studies of pathological resistance in human obesity.
Several technological advances would significantly advance leptin research in sheep and other large animal models:
Genetic tools:
Imaging techniques:
High-throughput methodologies:
Leptin is a hormone predominantly made by adipose cells and enterocytes in the small intestine that helps to regulate energy balance by inhibiting hunger. Leptin acts on cell receptors in the arcuate nucleus of the hypothalamus. In recent years, researchers have developed various leptin antagonists to study and potentially treat conditions related to leptin signaling, such as obesity and metabolic disorders.
The Leptin Antagonist Triple Mutant Ovine Recombinant, often referred to as Leptin tA Ovine, is a specially engineered protein designed to inhibit the action of leptin. This antagonist is a single non-glycosylated polypeptide chain containing 146 amino acids, with an additional alanine at the N-terminus. The molecular mass of this protein is approximately 16 kDa .
The Leptin Antagonist Triple Mutant is characterized by three specific mutations: L39A, D40A, and F41A. These mutations are introduced to disrupt the normal binding of leptin to its receptor, thereby inhibiting its biological activity. The protein is produced using recombinant DNA technology in Escherichia coli (E. coli) and is purified through proprietary chromatographic techniques .
The Leptin Antagonist Triple Mutant Ovine Recombinant is typically supplied as a white lyophilized (freeze-dried) powder. It is recommended to reconstitute the lyophilized protein in sterile water or sterile 0.4% NaHCO3 adjusted to pH 8, at a concentration of not less than 100 µg/ml. The protein is stable at room temperature for several weeks when lyophilized, but should be stored desiccated below -18°C for long-term storage .
This leptin antagonist is capable of inhibiting leptin-induced proliferation of BAF/3 cells that are stably transfected with the long form of the mouse leptin receptor. It also inhibits various leptin effects in several in vitro bioassays. This makes it a valuable tool for studying leptin signaling pathways and for potential therapeutic applications in conditions where leptin activity needs to be modulated .
Leptin antagonists, including the Leptin Antagonist Triple Mutant Ovine Recombinant, are used extensively in research to understand the role of leptin in energy homeostasis, obesity, and metabolic disorders. They are also being explored for their potential therapeutic applications in treating conditions such as obesity, diabetes, and other metabolic diseases .